McKesson (MCK)
(Delayed Data from NYSE)
$525.28 USD
-0.66 (-0.13%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $525.55 +0.27 (0.05%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$525.28 USD
-0.66 (-0.13%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $525.55 +0.27 (0.05%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
Zacks News
LabCorp's (LH) New Antigen Test to Spot Active COVID-19 Virus
by Zacks Equity Research
LabCorp's (LH) new antigen test is the newest development to detect COVID-19 infection at every single stage, from diagnostic testing to vaccination trails.
Should Value Investors Buy McKesson (MCK) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
The Zacks Analyst Blog Highlights: Align Technology, Henry Schein, McKesson Corp and Becton, Dickinson and Co
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Align Technology, Henry Schein, McKesson Corp and Becton, Dickinson and Co
4 Dental Stocks to Watch on Likely Industry Turnaround
by Zacks Equity Research
The dental equipment market seems ready to grow as it continues to recover from the COVID-19 pandemic slump, making it prudent to look at names like Henry Schein (HSIC) and McKesson (MCK)
Here's Why You Should Hold on to McKesson (MCK) Stock Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from the multi-year strategic growth initiative and strength in the Distribution Solutions segment.
Top Stock Reports for Oracle, Medtronic & AMD
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Oracle (ORCL), Medtronic (MDT), and Advanced Micro Devices (AMD).
McKesson (MCK) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
McKesson's (MCK) fiscal third-quarter 2021 results benefit from strong performance at Medical-Surgical Solutions segment.
McKesson (MCK) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
McKesson (MCK) delivered earnings and revenue surprises of 11.38% and 1.16%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
MedTech Stock Earnings on Feb 2: IDXX, MCK & More
by Urmimala Biswas
In Q4, MedTech stocks are expected to have gained from month-wise sales rebound in many states and regions. However, international sales might have been dampened.
McKesson (MCK) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
McKesson's (MCK) fiscal third-quarter results are likely to reflect solid show by U.S. Pharmaceutical and Specialty Solutions segment.
Thermo Fisher (TMO) Expands in Viral Vector With Henogen Buyout
by Zacks Equity Research
The addition of Henogen's manufacturing capabilities in Europe complement Thermo Fisher's (TMO) four development and manufacturing sites in North America.
Can McKesson (MCK) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
McKesson (MCK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
BD (BDX) Posts Upbeat Preliminary Fiscal First Quarter Results
by Zacks Equity Research
BD (BDX) projects its fiscal Q1 revenues to surge from the year-ago figure, primarily on the back of high demand for its COVID-19 diagnostic tests
Intuitive Surgical (ISRG) Up on Solid Preliminary Q4 Results
by Zacks Equity Research
Intuitive Surgical (ISRG) posts solid fourth-quarter and full-year 2020 result driven mainly by da Vinci procedure volume growth.
Pacific Biosciences (PACB) Releases Preliminary Q4 Revenues
by Zacks Equity Research
Pacific Biosciences' (PACB) preliminary Q420 revenues are expected to improve from Q320.
Here's Why You Should Invest in McKesson (MCK) Stock Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from multi-year strategic growth initiative and Distribution Solutions segment.
DexCom (DXCM) Posts Solid Preliminary Q4 and 2020 Revenues
by Zacks Equity Research
DexCom (DXCM) posts solid fourth-quarter and full-year 2020 revenue data on the back of resilience shown in the face of the COVID-19 induced challenges.
Nevro (NVRO) Posts Weak Preliminary Q4 and 2020 Revenues
by Zacks Equity Research
Nevro's (NVRO) preliminary worldwide Q4 revenues are expected to decline from the year-ago quarter's figure.
4 Sector ETFs & Stocks to Bet on Q4 Earnings
by Sweta Killa
Sectors with positive earnings growth in Q4 include autos (86.3% earnings growth), construction (27.2%), basic materials (7.6%), medical (6.3%), and aerospace (4.4%).
Why You Must Add Merit Medical (MMSI) Stock to Your Portfolio
by Zacks Equity Research
Investor optimism is high on Merit Medical (MMSI) stock, courtesy of solid prospects.
The Zacks Analyst Blog Highlights: McKesson, Cardinal Health, Becton, Dickinson and Co and Hill-Rom Holdings
by Zacks Equity Research
The Zacks Analyst Blog Highlights: McKesson, Cardinal Health, Becton, Dickinson and Co and Hill-Rom Holdings
4 Dividend-Paying Undervalued MedTech Stocks for Gains in 2021
by Urmimala Biswas
Here we discuss four dividend-paying value stocks, MCK, CAH, BDX and HRC, which though trading cheap now, have solid chances of a rebound in the second half of 2021.
AmerisourceBergen (ABC), WBA Ink Deal to Focus on Core Arms
by Zacks Equity Research
AmerisourceBergen (ABC) and Walgreens (WBA) enter into a key strategic deal to boost focus on core businesses, while extending their partnership.
NextGen's (NXGN) Platform Gets Adopted by FPA Women's Health
by Zacks Equity Research
FPA Women's Health utilizes NextGen's (NXGN) Virtual Visits, which are integral to the company's Patient Experience Platform
Why You Should Retain Veeva (VEEV) in Your Portfolio Now?
by Zacks Equity Research
Investor confidence/optimism is high on Veeva (VEEV) stock, driven by its solid prospects.